Meta-analysis shows no survival difference between intermediate-dose and high-dose cytarabine consolidation for AML, highlighting IDAC's superior safety profile.
Key Points
IDAC and HiDAC show similar overall survival rates, with pooled HR of 1.04 (95% CI, 0.82–1.32).
IDAC demonstrates fewer adverse events than HiDAC, particularly in terms of infections and myelosuppression.
This meta-analysis included 2,621 AML patients with a median follow-up of 20.7 months.
Further research is necessary for subgroup differences, especially involving core-binding factor AML.